TB-500
TB-500 is a seven-amino-acid fragment related to thymosin beta-4, commonly identified as the N-terminally acetylated sequence LKKTETQ. That fragment overlaps the actin-binding region of full-length thymosin beta-4, a 43-amino-acid peptide with extensive preclinical biology. The two are related. They are not interchangeable.
TB-500 is used in the community to support healing, mobility and recovery, based largely on promising repair biology related to thymosin beta-4.
Clinically not equivalent.
Most of the human evidence commonly cited around “TB-500” actually belongs to full-length thymosin beta-4—not to TB-500 itself.
TB-500 is not simply another name for thymosin beta-4.
FDA describes TB-500 as the N-acetylated heptapeptide N-acetyl-LKKTETQ, corresponding to amino acids 17–23 of full-length thymosin beta-4.
Full-length thymosin beta-4 contains 43 amino acids and has multiple biologically active regions. TB-500 captures the LKKTETQ segment associated with actin binding, cell migration and wound-healing biology.
The evidence usually cited is for the wrong molecule.
Full-length synthetic or recombinant thymosin beta-4 has been studied in humans, including randomized safety trials. For example, a 2010 placebo-controlled study evaluated intravenous synthetic thymosin beta-4 in healthy volunteers and reported that it was generally well tolerated over the study period.
But that trial does not establish the safety or efficacy of TB-500. FDA's 2026 review specifically stated that it did not identify human exposure data for drug products containing thymosin beta-4 fragment LKKTETQ, also known as TB-500.
Recovery claims often borrow credibility from full-length thymosin beta-4.
Community use is broad. TB-500-specific evidence is not.
Very high recovery interest
TB-500 is frequently discussed for soft-tissue injuries, tendon and ligament recovery, mobility and “systemic healing,” often alongside BPC-157.
- Injury-repair positioning
- Frequent pairing with BPC-157
- Often described as systemic rather than local
- Claims commonly blur TB-500 with thymosin beta-4
TB-500-specific data: essentially absent
Human studies exist for full-length thymosin beta-4, but FDA's current review found no human exposure data for TB-500 drug products.
- No established human TB-500 efficacy trials
- No FDA-approved TB-500 drug
- Human thymosin beta-4 evidence is not interchangeable
- Fragment-specific in-vivo wound evidence is limited
TB-500 is a textbook case of evidence transfer: a related molecule has interesting biology and some human data, while the marketed fragment inherits a reputation far stronger than its own evidence base.
What people are actually reporting.
Recurring community-use patterns are visible around TB-500. We document those patterns here without turning them into a clinical recommendation.
Public peptide discussions commonly describe a few milligrams per week, often divided across one or two administrations. “Loading” periods at higher weekly totals also appear, but there is no standardized community regimen.
No clinically established TB-500 dosing protocol exists for wound healing, tendon, ligament or muscle recovery in humans. FDA’s review distinguishes TB-500 from full-length thymosin beta-4 and states that human exposure data for TB-500 drug products were not identified.
Similarity does not equal safety equivalence.
TB-500 has no FDA-approved therapeutic use, and its human safety profile is not established.
FDA's current compounding safety-risk page says compounded TB-500 may pose immunogenicity risks for certain routes because of aggregation and peptide-related impurities. FDA also states that it has not identified human exposure data for TB-500 drug products and lacks important information about whether administration could cause harm.
FDA put the TB-500 / thymosin beta-4 distinction front and center.
Regulatory
FDA formally reviewed TB-500-related bulk drug substances.
The agency evaluated TB-500 free base and acetate for wound healing in the 503A Bulks List process and emphasized the lack of human exposure data and limited fragment-specific evidence.
Research
Researchers chemically identified TB-500 as Ac-LKKTETQ.
Analytical work characterized the N-terminally acetylated 17–23 fragment of thymosin beta-4 in products identified as TB-500, helping clarify what the compound actually was.
Research
Full-length thymosin beta-4 entered human safety testing.
A randomized placebo-controlled intravenous study in healthy volunteers reported short-term tolerability of synthetic thymosin beta-4. This is important human evidence—but it is evidence for thymosin beta-4, not TB-500.
Show the receipts—and label the molecule correctly.
| Evidence | Design | What it adds | What it cannot prove |
|---|---|---|---|
| Active-site biology · PMID 20179146 | Preclinical / mechanistic review and experiments | Identifies LKKTETQ as an active region of thymosin beta-4 linked with actin binding, migration and wound-healing biology. | Does not establish TB-500 clinical efficacy. |
| TB-500 characterization · PMID 22962027 | Analytical chemistry | Identifies TB-500 as the acetylated thymosin beta-4 17–23 fragment Ac-LKKTETQ. | Does not show therapeutic benefit or safety. |
| Full-length thymosin beta-4 safety · PMID 20536472 | Randomized placebo-controlled human study | Provides short-term human safety and PK data for synthetic thymosin beta-4. | Cannot be assumed to apply to TB-500. |
| Recombinant thymosin beta-4 safety · PMID 34346165 | First-in-human randomized phase I study | Adds additional human safety and PK data for full-length thymosin beta-4. | Still not TB-500-specific evidence. |
| FDA 2026 TB-500 review | Regulatory evidence review | Documents lack of human exposure data and limited TB-500-specific wound-healing evidence. | Does not determine what future controlled TB-500 trials might show. |
What the latest evidence supports—and does not
Human evidence: Full-length thymosin beta-4 (TB4) and the fragment commonly called TB-500 are not interchangeable research interventions. A 2026 scoping review found that most relevant studies evaluated TB4, while direct TB-500 evidence was minimal. Human ocular and wound findings involving TB4 do not prove that TB-500 injections improve musculoskeletal recovery.
Regulatory and safety context: FDA reported that it had not identified human clinical studies or human exposure data for the TB-500 fragment it evaluated. The agency highlighted unknown safety and potential immunogenicity or aggregation concerns. Its compounding review is not drug approval.
Source documents: 2026 scoping review distinguishing TB4 and TB-500 ↗ · FDA TB-500 briefing document (July 2026) ↗ · FDA July 2026 advisory committee ↗
Editorial boundary: Community Protocol Signal describes discussion patterns, not validated dosing or treatment advice. Evidence from other molecules, routes, or indications must not be transferred automatically.
Read deeper.
Follow the evidence.
BPC-157
Compare two of recovery culture's most popular peptides—and two of its largest evidence gaps.
Recovery
Explore injury, tissue repair and recovery biology without starting from a compound.
Evidence belongs to the molecule studied.
See why related peptides cannot automatically inherit each other's clinical evidence.
Community Pulse
Track how recovery compounds gain momentum—and how scientific distinctions disappear in online discussion.